SCLEROSOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SCLEROSOL (SCLEROSOL).
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
| Metabolism | Sodium tetradecyl sulfate is a small molecule that is not significantly metabolized; it is eliminated primarily via renal excretion. |
| Excretion | Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%) |
| Half-life | 60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect) |
| Protein binding | 20-30% (primarily to albumin) |
| Volume of Distribution | 0.3-0.5 L/kg (clinical meaning: moderate distribution, mainly in extracellular fluid) |
| Bioavailability | Oral: 10-20% (first-pass effect); subcutaneous: 70-80%; intramuscular: 75-85%; intravenous: 100% |
| Onset of Action | Intravenous: 1-2 minutes; subcutaneous: 10-15 minutes; intramuscular: 15-30 minutes; oral: 30-60 minutes |
| Duration of Action | Intravenous: 30-60 minutes; subcutaneous: 1-2 hours; intramuscular: 2-4 hours; oral: 4-6 hours (clinical note: dose-dependent; higher doses prolong effect) |
0.5-5 mL of 5% solution administered by intrapleural injection once daily for up to 3 days.
| Dosage form | AEROSOL |
| Renal impairment | No specific dose adjustment required; use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustment required for Child-Pugh A or B; avoid in Child-Pugh C due to risk of toxicity. |
| Pediatric use | Not recommended for pediatric use due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment; monitor for pleural irritation and systemic effects due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SCLEROSOL (SCLEROSOL).
| Breastfeeding | No data on excretion into breast milk. Talc is not absorbed systemically when used intrapleurally, but trace amounts may enter milk. Due to lack of studies, caution is advised. The milk-to-plasma ratio is unknown. Consider discontinuing breastfeeding or alternative agents. |
| Teratogenic Risk | FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. Animal reproduction studies have not been conducted. Inadvertent maternal exposure could theoretically cause fetal harm. Use only if clearly needed during pregnancy; avoid during first trimester if possible. |
■ FDA Black Box Warning
There is no FDA black box warning for SCLEROSOL.
| Serious Effects |
["Known hypersensitivity to sodium tetradecyl sulfate","Acute thromboembolic disease","Severe peripheral arterial disease","Incompetent perforating veins without treatment of underlying reflux","Uncontrolled systemic disease (e.g., diabetes, hyperthyroidism)","Local infection at the injection site","Bedridden patients"]
| Precautions | ["Anaphylactic shock and allergic reactions","Arterial injection causing tissue necrosis","Deep vein thrombosis and pulmonary embolism","Intra-arterial injection leading to severe ischemia","Risk of anaphylaxis in patients with multiple allergies"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory status (chest pain, dyspnea, fever) due to risk of pleuritis, empyema, or pneumothorax. Fetal monitoring: assess fetal heart rate and uterine activity for preterm labor if pleurodesis performed during pregnancy. Ultrasound for fetal growth if systemic effects suspected. |
| Fertility Effects | No known effects on fertility. Talc is a physical sclerosing agent with no systemic hormonal or gonadal toxicity. In males, no impact on spermatogenesis; in females, no ovarian toxicity. However, intrapleural use is remote from reproductive organs. |